SERA
SERA PROGNOSTICS, INC.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$2.03
−1.46%Year over year
Reported trailing growth
- Revenue
- -35.2%
- EBITDA
- -1.6%
- EBIT
- -1.2%
- EPS
- +21.2%
- Free cash flow
- -4.5%
- Operating cash flow
- -5.3%
Forward estimates
Based on analyst estimates
- Revenue
- +1935.7%
- EBITDA
- +13.0%
- EPS
- +14.4%
Three-year CAGR
- Revenue
- -32.9%
- EBITDA
- +3.3%
- EBIT
- +0.4%
- Net income
- +2.9%
- EPS
- +32.3%
- Free cash flow
- -72.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026